Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Anavex Life Sciences reports Q1 results, highlights precision medicine focus

Anavex Life Sciences showcased positive results in the Alzheimer's study and emphasized precision medicine in addressing neurological disorders.
The company's financial performance, with a net loss of $13 million and a cash position of $143.6 million, reflects ongoing research and development efforts.
Challenges include financial losses, regulatory discussions, and operational complexities, while opportunities lie in upcoming data readouts and new clinical trials.
Overall, Anavex's strategic focus on precision medicine and diverse pipeline position it for potential growth and advancements in neurological treatments.

Anavex Life Sciences reports Q2 results, eyes pipeline expansion

Anavex Life Sciences reported a mixed financial performance in Q2 2023 but maintains a strong cash position for future operations and clinical programs.
The company's focus on Alzheimer's disease treatments, pipeline expansion, and team strengthening reflect a commitment to advancing innovative therapies.
While facing financial challenges and competitive pressures, Anavex has opportunities to leverage its clinical successes, new hires, and partnerships for future growth.

Anavex Life Sciences reports Q3 loss, eyes neurology breakthroughs

Anavex Life Sciences is actively pursuing clinical advancements in neurology with a focus on blarcamesine. Despite financial challenges, the company's strategic partnerships and pipeline expansion position it well for future growth and innovation.

Anavex Life Sciences reports strong cash position amidst strategic focus

Anavex Life Sciences demonstrated financial strength with a substantial cash position in Q4 2023, while facing challenges with a net loss.
The company's strategic focus on precision medicine programs and ongoing trials presents opportunities for growth and innovation in the healthcare sector.
Navigating regulatory processes and balancing financial sustainability will be key for Anavex to capitalize on its strengths and address operational challenges.

Anavex Life Sciences reports Q1 loss but advances precision medicine

Anavex Life Sciences reported financials reflecting a net loss but with a solid cash position, emphasizing fiscal responsibility and ongoing research progress.
The company's strengths lie in its financial stability, innovative precision medicine focus, and commitment to addressing neurological disorders.
Challenges include managing financial losses, meeting regulatory timelines, and balancing fiscal prudence with research investments.
Opportunities arise from upcoming submissions, precision medicine trends, therapeutic expansion, and potential collaborations.

Anavex Life Sciences reports Q2 progress amidst analyst inquiries

Anavex Life Sciences is actively pursuing the development of therapies for various neurological disorders. The company faces challenges in FDA guidance interpretation, European filings, and commercialization strategies. However, with a solid cash position and a focus on transformative therapies, Anavex has significant growth opportunities.

Anavex Life Sciences reports Q3 results, advances precision medicine

Anavex Life Sciences showcased financial stability with a strong cash position despite reporting a net loss, underlining their commitment to advancing treatments for brain disorders.
Progress in trials for blarcamesine in Alzheimer's disease and other neurological conditions signals potential breakthroughs in precision medicine.
While facing challenges such as managing losses and regulatory uncertainties, Anavex remains poised to leverage opportunities through upcoming data releases and regulatory submissions.

Anavex Life Sciences reports stable finances and promising clinical advancements

Anavex Life Sciences showcased financial stability, positive clinical trial outcomes, and a commitment to advancing treatments for neurological disorders.
While facing challenges in managing net losses and regulatory processes, the company remains well-positioned to capitalize on opportunities for growth and innovation.
Investors can be optimistic about Anavex's progress in developing potential treatments for Alzheimer's disease and schizophrenia, supported by a strong financial foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the H. C. Wainwright Global Investment Conference 2022 on Wednesday, May 25, 2022, at 12:00 PM ET.

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer. Conference Call Participants Yun Zhong - BTIG Pete Stavropoulos - Cantor Operator Welcome to the Anavex Life Sciences Fiscal 2022 Second Quarter Conference Call.

Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2022 Results - Earnings Call Transcript

Company to host a webcast today at 4:30 p.m. Eastern Time

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

San Diego, California--(Newsfile Corp. - May 6, 2022) - Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal securities laws by Anavex Life Sciences Corp. ("Anavex Life Sciences" or "the Company") (NASDAQ: AVXL).On February 1, 2022, Anavex Life Sciences announced a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following this news, a Senior Writer at Statnews stated, "Anavex changed the primary and secondary endpoints...

(AVXL) News: Did You Lose Money on Anavex Life Sciences Corp. Investment? Contact Johnson Fistel Regarding Class Action Investigation

Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett Syndrome Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett Syndrome

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022, at 11:00 AM ET.

Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Anavex Management Team will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 3:45 PM ET.

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- #ANAVEX273--WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors With Losses to Inquire About Securities Class Action Investigation – AVXL

New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs...

ROSEN, A TOP RANKED LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation - AVXL

NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Anavex Management team will participate in the Rare Neurodevelopmental Disorders Panel at the Cantor Virtual Rare Disease Summit on Wednesday, March 30, 2022 at 11:00 AM ET.

Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit

Aricept and blarcamesine limit further oxidative stress in Alzheimer's disease via agonism of Sigma-1 receptors. Simufilam may do the same.

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

Boston, Massachusetts--(Newsfile Corp. - March 21, 2022) - Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in their Anavex Life Sciences Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/avxl.What is this all about?Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3...

Anavex Life Sciences Corp. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

NEW YORK , March 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation - AVXL

Anavex Life Sciences Corp (NASDAQ: AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS1 Total score improved significantly by -14.51 for.

Anavex Life Sciences Highlights Biomarker Data From Parkinson's Disease Dementia At International Conference

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the Annual Needham Virtual Neuroscience Forum in a fireside chat on Wednesday, March 16th 2022 at 8:00 AM ET.

Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the Company's possible violations of federal securities laws. If you suffered a loss on your Anavex investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors

NEW YORK, March 7, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation - AVXL

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the Company's possible violations of federal securities laws. On February 1, 2022, before the market opened, Anavex announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following the announcement, several people on social media i

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 1, 2022, before the market opened, Anavex announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoint

The Law Offices of Frank R. Cruz Continues Its Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it has changed its auditors from BDO USA LLP (“BDO“) to Grant Thornton LLP (“Grant Thornton“).

Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

New York, New York--(Newsfile Corp. - February 22, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs...

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses to Inquire About Securities Class Action Investigation - AVXL

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation - AVXL

New York, New York--(Newsfile Corp. - February 16, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs...

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation - AVXL

News for Anavex Life Sciences Stock (AVXL)